As I regularly engage with pharma executives and biotech founders, a common theme inevitably arises: why is precision medicine taking so long to become a reality, and is technology to blame
Roche is reported to be considering the sale of its cancer data specialist Flatiron Health, just a few years after it bought the company for $1.9 billion.
Value-based care is at the centre of industry discussions at the moment, not only advancing quality and equity in healthcare, but also accelerating innovation in care delivery.
